會員登入
註冊
隨著國際醫療水準提升，精準快速的診斷、以及對醫材的需求更是扶搖直上。臺灣以堅實的醫材研發及製造能量，配合精準醫學的資源投注穩健立足於亞太中心。本次展望會匯聚來自診斷檢測、再生醫材、智慧手術等業界頂尖技術團隊，耀眼展示最新發表、邁出國際新「財」路！
開啟商機，立即註冊!
BioGend Therapeutics Co.,Ltd.
博晟生醫股份有限公司
The project management teams at BioGend Therapeutics are led by seasoned product development managers with team members from different functional areas. Each development project is carefully planned following the phase-gate process for effective and efficient execution. For highly regulated biomedical devices, the expertise in regulatory affairs and pre-clinical and clinical development is essential in order to gain regulatory approval and to realize the potential value of innovative bio-technologies. Through the development of innovative bio-orthopaedic products and the establishment of world class GMP processes, we hope to elevate Taiwan's biomedical industry to a new level.
Phalanx Biotech Group
華聯生物科技股份有限公司
Phalanx Biotech’s expertise is in expression profiling and genetic analysis which stems from its excellence as an original design manufacturer of gene expression microarrays, CytoOneArray®, targeted chromosomal microarrays, for prenatal and postnatal CNV (copy number variation) test services. Its third-generation chromosomal microarrays can test for more than 500 types of hereditary and congenital disorders.
Apart from that, Phalanx Biotech’s patented SNP technology can be used to assess risk of obesity, cardiovascular disease, Parkinson's disease, cancer, etc. in population medicine. It provides an all-in-one of value at risk for +17 common cancers and +13 chronic diseases by genetic tests from our SNP (single nucleotide polymorphism) microarray for personal health and risk assessment.
Especially, Phalanx pertains an exclusive patent for Liver ctDNA Methylation Test
for the earliest stages of liver cancer detection - A breakthrough genetic testing development by leveraging DNA methylation markers. The sensitivity and specificity of LiverEDx reach to 84.2% and 83.0%, respectively, with AUC=0.87.
HCmed Innovations Co., Ltd.
心誠鎂行動醫電股份有限公司
HCmed Innovations focuses on the development of drug-device combination products for inhalation therapy. It develops and manufactures portable vibrating mesh nebulizers that offer a mature customization platform, aiming to enhance drug delivery. This technology enables efficient and reliable nebulization of different types of medication, ranging from small molecule synthetics to large molecule biologics, as either solutions, suspensions or even difficult-to-deliver high viscosity drugs.
By combining the strength of Taiwan’s world-class manufacturing industry and a well-established GMP certified manufacturing facility, HCmed’s products have received approval from multiple international health authorities, with some of them being launched in selected markets. Furthermore, the latest developments embrace the inclusion of more advanced features, such as breath actuation and connectivity in order to improve drug delivery efficacy and reinforce patience adherence.
HCmed is prompt to expand its over-the-counter and combination development to continue bringing significant value to the respiratory field and help all those who require their inhalation treatment.
Applied BioCode
瑞磁生物科技集團股份有限公司
The company develops, manufactures, and commercializes multiplex diagnostic testing products. Applied BioCode is the owner of proprietary ‘Barcoded Magnetic Beads’ (BMB) technology, a bio-barcode realized through semiconductor fabrication. The microscale BMB, with a diameter of human hair, is tagged with immunochemistry or molecular probes, allowing the digital barcode to be easily scanned and accurately identified for a very high number (4,096 barcodes) of biological targets with no ambiguity.
Applied BioCode products focus on the $10 billion molecular diagnostic infectious disease market, with an emphasis on Syndromic Testing, a high value methodology that detects all syndrome causing pathogens, while Applied BioCode offers flexible reporting, at affordable cost. The US FDA 510k cleared assays include BioCode® MDx-3000 system with a 17-plex Gastrointestinal Pathogen Panel (GPP) and a 17-plex Respiratory Pathogen Panel(RPP). The 2 US FDA EUA approved assays include BioCode® SARS-CoV-2 Assay that detects 2 N-genes, and BioCode® SARS-Cov-2 Assay that allows pooled samples of 5 specimens. Applied BioCode continues to develop and commercializes novel syndromic testing options for Fungi, unitary track, women STDs, and bacterial drug resistance.
Proprietary BMB also applies to wide spectrums of diagnostics outside of infectious disease. Applied BioCode partners with world Pet Diagnostics leader Idexx in vet applications. While food safety, autoimmune diagnostics, allergen testing, liquid biopsy are all in line to roll out through either self development or partnership.
V-CHECK Inc.
維致生醫科技股份有限公司
維致生醫科技股份有限公司是一家提供精準檢測產品及服務之創新型研發生技公司。致力於女性疾病之生物標記篩選，以增進婦女健康為宗旨，設計開發準確且便利病患檢測之體外診斷試劑產品，以期達到「早期診斷、早期改善、早期治療」為目標。
維致生醫第一項女性精準檢測系列產品「子宮內膜異位症體外檢測技術- Vido Care Endometriosis test」採用非侵入性的血液檢測，擁有媲美黃金診斷標準的侵入式腹腔鏡診斷性能，敏感性及特異性皆逾90％。Vido Care系列產品擁有全球化智慧財產權佈局，專利獲21國保護；已獲歐盟CE認證及ISO13485:2016認證，將於2021年進行歐美臨床收案與驗證。
MedFluid Co., Ltd.
醫流體股份有限公司
醫流體股份有限公司(MedFluid Co., Ltd.)成立於西元 2019 年 5 月,團隊成員由平均 40 歲以下的成員所組成,是一家年輕且充滿活力的公司。
本公司之專業技術是以氣動式微流體為核心並結合自動化操作機台,進行液態檢體檢測的體外診斷醫療器材。醫流體團隊結合國內生醫、機械、及光機電整合軟硬體相關人才，目前已與國內醫療器材大廠、頂尖學術研究機構、國內外醫學中心合作,除了共同努力開發創新檢測技術外,也協助提供完整檢測所需的儀器服務及試片耗材。
醫流體致力於成為全球微流體生醫檢測技術的新創黑馬,希冀提供完善的個人化藥物精準醫療。
PlexBio Co., Ltd.
博錸生技股份有限公司
博錸生技多年來鑽研腫瘤基因突變之液態檢體（Liquid Biopsy）自動化檢測平台開發，以實現精準醫療(Precision Medicine)之臨床診斷、癌症早期檢測、動態監控、復發預測與預後評估，為癌症治療提供精準數據，是未來預防醫學治療的主流趨勢。InterlliPlex TM博錸多重肺癌基因檢測平台，使用博錸影像晶元磁片πCodeTM來偵測非小細胞肺癌(NSCLC)的血漿或組織切片檢體中74個DNA突變位點及28個融合位點。此技術可擴展並涵蓋數百個基因突變位點，非侵入式的液態檢體可同時針對大量病患的檢體進行分析。博錸產品主要的銷售歐美、日本、台灣、中國及東南亞各地，為領先業界的體外診斷試劑開發專家。
LumiSTAR Biotechnology, Inc.
昱星生物科技股份有限公司
昱星生技聚焦於人類誘導式幹細胞（iPSC) 模組之高效能藥物篩檢及毒性測試平台，以及更進一步將此平台技術提供做為個人化、精準化醫療服務之檢測技術。
主要核心技術為生理蛋白指示劑之開發 (genetically encoded tools)，可用於細胞生理或特定胞器之長時間追蹤; 以及人類誘導式幹細胞 (iPSC) 相關技術之藥物篩檢應用；並結合光遺傳學工具的設計，提供藥廠及 CRO 公司做大規模的新藥開發及毒性測試。此平台技術另一方面可應用於高效能精準化、個人化醫療之服務，亦為公司發展之重點項目。
Brain Navi Biotechnology
鈦隼生物科技股份有限公司
首發的「自動鼻咽採檢機器人」可讓醫護人員不用直接接觸受檢者執行採檢，避免交互感染。機器人可客製化受檢者的鼻咽深度（測量個人鼻翼至耳垂的角度及深度）來抵達個人鼻咽位置而採取足夠檢體及減少異物感。了解臨床的環境需求後，於2020年年底向經濟部提出「零接觸防疫採檢站」- 一站式整合性服務；將採檢、轉液（此步驟原本需將檢體運送至實驗室，由醫檢師穿戴防護衣，將檢體移入病毒保存液(UTM)）至產生報告精簡於醫療級貨櫃屋內。其內配備完整安全環境：HEPA 系統、紫外線消毒系統、正負壓淨流系統等。「零接觸防疫採檢站」能大力協助受嚴峻疫情困頓的醫護人員，將採檢流程標準化可快速完成檢測並取得正式的核酸檢測報告。
Helios Bioelectronics Inc.
瀚源生醫股份有限公司
瀚源生醫創立於2016年，致力於發展應用導向、具高靈敏度的BioFET平台，即時監測健康狀態，以提供精準醫療所需的資訊。瀚源生醫的平台可有效應用於收集基因變異及蛋白質表現異常等資訊，來建立針對生物分子調控之動態檢測，幫助監測與診斷複雜的疾病。
ACT Genomics
行動基因生技股份有限公司
行動基因為亞洲癌症精準醫療的領導者，我們持續關注生物標記物發展，透過基因檢測、疾病與藥物分析，提供癌症治療之最佳方針，我們提供:
▪ 通過美國病理師協會(CAP)認證的實驗室以執行高靈敏度與高特異性之次世代定序(NGS)檢測
▪ 提供藥廠合作夥伴在藥物開發時所需之生物標記物研究、臨床試驗之病患篩選及伴隨式診斷檢測開發
▪ 亞洲基因資料庫，提供藥廠臨床試驗病患轉介服務
▪ 專業生物資訊團隊及醫藥資訊團隊，將複雜的基因資訊轉化為可實行的治療方案，協助醫師在不同治療階段，依據每位病患的基因特性找出最適合的治療策略。
TBG Biotechnology Corp.
德必碁生物科技股份有限公司
